Table 5. Assessment of changes in inflammatory biomarker levels between groups.
Visits | EnMax | Placebo | Marketed reference |
C-reactive protein levels (mg/dL) | |||
Visit 1 | 10.84± 2.95 | 10.60±3.26 | 11.02±3.79 |
Visit 4 | 5.28±2.08 (51.24%) | 8.18±2.60* (22.82 %) | 7.14±2.09 (35.23 %) |
P-value | <0.001 | <0.001 | <0.001 |
Visit 1 | 22.77± 5.41 | 21.58±5.29 | 23.38 ±5.88 |
Visit 4 | 9.15±4.79 (59.80 %) | 15.19±6.32* (29.59%) | 12.54±5.06 (46.38 %) |
P-value | <0.001 | <0.001 | <0.001 |